Authors


Patricia Malone

Latest:

Once Upon a Brand

The key ingredients for biopharma startups in building their brand story.


Robert Finkel

Latest:

Once Upon a Brand

The key ingredients for biopharma startups in building their brand story.


Shaun McMahon

Latest:

Pre-launch Prep: The Modern Protocol

Tech-driven changes to training and learning systems-and how brand information is provided and shared-are overhauling approaches to sales rep preparation.


Jon Hesby

Latest:

Post-Launch Birthday: The Time to Refine

Following a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.


Melissa McDevitt

Latest:

Post-Launch Birthday: The Time to Refine

Following a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.


Esin Izat

Latest:

To Reduce Commercial Risk for Orphan Drugs, Transform Forecasting

To successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.


Rafael Cosentino

Latest:

Pharmaceutical Native Advertising

A look into how native advertising works, what cost benefits they provide, and measuring their success.


Subbarao Jayanthi, Frank Koos, Melissa Morales

Latest:

Commercialization Imperatives for Success in Rare Diseases

To ensure patients have timely access to expensive new therapies, biopharma companies have to address commercialization challenges with innovative measures, even after getting regulatory approval.


Alan White

Latest:

Money Isn't Everything: Beating Salary Inflation

Alan White explores alternative ways for life sciences firms to keep hold of experienced, qualified professionals as demand for pharmacovigilance skills soars.


Kevin Troyanos

Latest:

Value-Based Agency Contracting Clears a Path to Better Outcomes for All

The healthcare industry’s ongoing shift from volume- to value-based contracting has set a compelling precedent for forward-thinking healthcare marketing agencies.


Hudson Plumb

Latest:

Value-Based Agency Contracting Clears a Path to Better Outcomes for All

The healthcare industry’s ongoing shift from volume- to value-based contracting has set a compelling precedent for forward-thinking healthcare marketing agencies.


Sathyanarayanan Krishnamurthy

Latest:

Pharma 4.0: Redefining Product Development and Regulatory Operations

Sathyanarayanan Krishnamurthy looks at the potential impact of Pharma 4.0 on product development and regulatory operations.


Bryan O’Malley, Brand Insights Contributor, Head of Digital, Fingerpaint

Latest:

Three Technologies that Can Move Your Brand

The rise of digital has enhanced our ability to personalize our marketing messages and engage our target audiences more effectively


IQVIA Biotech

Latest:

Launch Strategies: Trends and Challenges for Biotech Companies

Michael Kleinrock, of The IQVIA Institute for Human Data Science, will moderate a panel of launch and market access experts, as they discuss how biotech companies have addressed some key challenges to achieve launch success. Specific points will include an assessment of the overall outlook, what makes launches excellent, how to determine your optimal strategy, and questions that need to be addressed when deciding whether to launch or to partner. Live: Wednesday, Oct. 23, 2019 at 10am EDT On demand available after airing until Oct. 23, 2020 Register free


Nora Tsivgas

Latest:

For Payer Research, High Stakes are the Mother of All Invention

As payers increasingly stifle new drug launches, investors in biopharmaceutical companies pursue better sources of insights.


Bryan O’Malley

Latest:

Technology and Patients Intersect at Digital Pharma East

A look at highlights from the Digital Pharma East conference looking at technology and marketing innovation in pharma.


Alexander Bedenkov, MD, PhD

Latest:

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.


Andrey Ipatov, MD

Latest:

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.


Filip Surmont, MD

Latest:

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.


Carmen Moreno

Latest:

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.


Maarten Beekman, MD

Latest:

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.


Ryan Bate

Latest:

Silent (R)evolution in Medical Affairs Through the Power of Partnerships and Collaborations

A look at how Medical Affairs is transitioning to a new and fundamental strategic role within pharma and ways MA can step up to own this role within a pharma company, particularly within emerging markets.


Zachary Wessler

Latest:

Who is Driving the HTA Bus? And Where is it Headed?

An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.


Samar Malik

Latest:

Who is Driving the HTA Bus? And Where is it Headed?

An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.


Justin J. Piacentino

Latest:

Who is Driving the HTA Bus? And Where is it Headed?

An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.


Jeffrey J. Lemay

Latest:

Who is Driving the HTA Bus? And Where is it Headed?

An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.


Harshali K. Patel, PhD

Latest:

Who is Driving the HTA Bus? And Where is it Headed?

An Exploration of the Future of Pharmaceutical Value Assessments in the U.S.


Mike Kean and Billy Tamulynas

Latest:

Lay the Tech Foundation for IPO Success

Mike Kean and Billy Tamulynas discuss the key components of growth-ready technology for early-stage pharma companies and how to make optimal use of them.


Gabrielle Manoff

Latest:

Driving Success in Gene Therapy

Getting real about the R&D capabilities required to win in the gene therapy space.


Katelin Patterson

Latest:

Driving Success in Gene Therapy

Getting real about the R&D capabilities required to win in the gene therapy space.

© 2025 MJH Life Sciences

All rights reserved.